Shares of Cynapsus Therapeutics Inc. (NASDAQ:CYNA) saw unusually-high trading volume on Friday . Approximately 588,291 shares were traded during trading, an increase of 27% from the previous session’s volume of 462,602 shares.The stock last traded at $39.69 and had previously closed at $39.70.

CYNA has been the subject of several recent analyst reports. Noble Financial reaffirmed a “buy” rating and set a $50.00 price objective on shares of Cynapsus Therapeutics in a research report on Tuesday, August 30th. BMO Capital Markets set a $30.00 price objective on shares of Cynapsus Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, August 16th. Finally, Janney Montgomery Scott initiated coverage on shares of Cynapsus Therapeutics in a research report on Wednesday, June 15th. They set a “buy” rating and a $24.00 price objective for the company.

The company has a 50-day moving average price of $18.69 and a 200-day moving average price of $14.83. The company’s market capitalization is $492.47 million.

Cynapsus Therapeutics (NASDAQ:CYNA) last released its earnings results on Thursday, August 11th. The company reported $0.83 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.77) by $1.60. Equities analysts forecast that Cynapsus Therapeutics Inc. will post ($3.15) EPS for the current fiscal year.

Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.